Top 5 Health Care Stocks That May Surge - Graphite Bio (NASDAQ:GRPH), Fate Therapeutics (NASDAQ:FATE)Benzinga • 01/10/23
Why Vera Stock Crashed 60% On Its 'Positive' Kidney Drug Update — And Chinook PoppedInvestors Business Daily • 01/04/23
Vera Therapeutics Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA NephropathyGlobeNewsWire • 01/03/23
Vera Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 12/20/22
Vera Therapeutics to Host Key Opinion Webinar on Targeting the Source of IgA Nephropathy (IgAN) Featuring Jonathan Barratt, Ph.D., FRCPGlobeNewsWire • 11/17/22
Vera Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial ResultsGlobeNewsWire • 11/09/22
Vera Therapeutics Presents New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy and Positive Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection at the American Society of Nephrology Kidney WGlobeNewsWire • 11/05/22
Vera Therapeutics to Present Final Phase 2 Results of MAU868 in Kidney Transplant Recipients with Reactivated BK Virus Infection and New Analysis of Phase 2a JANUS Trial of Atacicept in IgA Nephropathy at the American Society of Nephrology Kidney Week 202GlobeNewsWire • 10/17/22
Wall Street Analysts Think Vera Therapeutics, Inc. (VERA) Could Surge 64%: Read This Before Placing a BetZacks Investment Research • 09/15/22
Wall Street Analysts See a 76% Upside in Vera Therapeutics, Inc. (VERA): Can the Stock Really Move This High?Zacks Investment Research • 08/29/22
Can Vera Therapeutics, Inc. (VERA) Climb 79% to Reach the Level Wall Street Analysts Expect?Zacks Investment Research • 08/12/22
Vera Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial ResultsGlobeNewsWire • 08/10/22
Vera Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare ConferenceGlobeNewsWire • 08/04/22
Vera Therapeutics Completes Patient Enrollment in Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA NephropathyGlobeNewsWire • 07/06/22
Vera Therapeutics Reports Positive Interim Phase 2 Data Showing MAU868 Has Significant BK Antiviral Activity in Kidney Transplant PatientsGlobeNewsWire • 06/04/22
Vera Therapeutics Announces New Atacicept Phase 2 Clinical Data in Two Oral Presentations at the 59th European Renal Association CongressGlobeNewsWire • 05/20/22
Vera Therapeutics Provides Business Update and Reports First Quarter 2022 Financial ResultsGlobeNewsWire • 05/16/22
Vera Therapeutics Announces Two Oral Presentations at the 59th European Renal Association – European Dialysis and Transplant Association Congress Featuring New Clinical Data on Atacicept in IgA Nephropathy and in Systemic Lupus ErythematosusGlobeNewsWire • 05/03/22
Vera Therapeutics Selected to Present Interim Phase 2 Data for MAU868 to Treat BK Virus in Kidney Transplant Patients as Oral Late-Breaker at the American Transplant Congress 2022GlobeNewsWire • 05/02/22